EU Survey on COVID-19 therapeutics


The purpose of this EU survey is to gain understanding on the needs of companies/organisations in the EU working on the development of new and repurposed medicines for COVID-19 therapeutics, i.e. medicines specifically developed for an indication in treatment of COVID-19. 

The European Commission has as a key objective to help accelerate the development of these medicines. Your answers will help us shape EU support in the best possible way.


We encourage you to participate in this EU Survey and respond at the latest by the 25th of June 2021. We welcome your answers as soon as possible in this urgent matter.


This survey is run by the European Commission, Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs, Unit D.2 – Industrial Forum, Alliances and Clusters (hereinafter “DG GROW Unit D.2”), on behalf of the European Commission’s Task Force for Industrial Scale Up of COVID19 Vaccines and Therapeutics. DG GROW Unit D.2 acts as data controller.


The European Clusters Alliance and the Council of European Bio Regions act as data processors. Please consult our privacy statement for more information about the processing and the protection of your personal data.


If you have any questions, please do not hesitate to contact:

European Commission – data controller

Eva Revilla


European Clusters Alliance

Nina Hoppmann


CEBR - Council of European Bioregions

Anais Le Corvec



to the survey